# Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency

> **NCT04073017** · NA · TERMINATED · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 11 (actual)

## Conditions studied

- Neuroendocrine Tumor
- Carcinoid Syndrome

## Interventions

- **DIETARY_SUPPLEMENT:** Enterade®
- **OTHER:** Functional Assessment of Chronic Illness Therapy for Patients with Diarrhea (version 4.0)

## Key facts

- **NCT ID:** NCT04073017
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-11-04
- **Primary completion:** 2021-05-18
- **Final completion:** 2021-05-18
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2021-05-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04073017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04073017, "Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04073017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*